Devices and Diagnostics

2016 Promises to Disrupt Dry Eye

Drugs & Devices for Dry Eye - Ophthalmology Innovation Summit 2015

This year promises to deliver disruption to the dry eye disease market as companies work to roll out new drugs, devices, and diagnostics. Shire may deliver the biggest success. The company is close to bringing a second therapeutic to the market to treat dry eye conditions, as lifitegrast is currently awaiting US regulatory approval. If…

Read More

Close-Up Look at Progress in Surgical Presbyopia Correction

Close-Up Look at Progress in Surgical Presbyopia Correction - OIS News

Presbyopia, the age-related loss of accommodation and near/reading vision, typically begins at about age 40 and affects nearly everyone over age 50. This huge opportunity is inviting several companies to pursue disruptive approaches. Stephen Lane, MD, from the University of Minnesota, opened the Breakfast Breakout session at OIS@AAO with an overview of current presbyopia treatment…

Read More

FDA Looking to Follow Up on Year of “Firsts”

OIS@AAO - Breakfast with the FDA

If you’re an executive at an ophthalmic drug development company and desire a frank discussion on regulatory issues that are critical to your business, you’d certainly jump at the chance to invite to breakfast Wiley Chambers, MD, deputy director of the Division of Transplant and Ophthalmology Products within FDA’s Center for Drug Evaluation and Research.…

Read More

Glaucoma Getting a Wake-Up Call

Glaucoma Getting a Wake-Up Call

SAN FRANCISCO — Thanks to a pending boom in minimally invasive glaucoma surgery (MIGS) devices, the global glaucoma device market is poised to come out of its long slumber and triple over the next five years, participants at the fifth annual “Glaucoma 360-New Horizons Forum” heard. Sponsored by the non-profit Glaucoma Research Foundation, the forum…

Read More

Exploring the Keys to Combination Therapies in Retina

OIS@AAO - Combination Therapies for Wet AMD & DME

The keys to developing combination therapies to treat retinal diseases lie in clinicians being able to better identify biomarkers for disease progression, developing strategies for staging disease, and finding a place for agents that act on disease pathways other than vascular endothelial growth factor, say ophthalmology leaders. Participants at a breakfast panel at OIS@AAO explored…

Read More

Taking in the View of 2015 & Beyond

Taking in the View of 2015 & Beyond

This year’s Ophthalmology Innovation Summits are behind us. We’re piling content onto OIS.NET including the 2015 Year in Review by OIS Founder and Co-Chair Emmett Cunningham, MD. And, believe it or not, we’re eagerly accepting registration for our next OIS@ASCRS, which will be held on May 5 at the InterContinental New Orleans. (We are now…

Read More

A Record-Setting OIS

A Record-setting OIS

Last week’s Ophthalmology Innovation Summit drew nearly 1,000 attendees to Las Vegas’ Planet Hollywood hotel, marking the largest OIS event we’ve held yet. The size of the audience only added to the energy of what’s becoming a kickoff tradition for the American Academy of Ophthalmology’s annual meeting. Three dozen ophthalmology companies – representing Drug Delivery,…

Read More

Biggest OIS Ever Set to Deliver News & Insights

Biggest OIS Ever Set to Deliver News & Insights

The maturation and advance of the ophthalmology sector will be fully evident tomorrow as we host the largest Ophthalmology Innovation Summit in its seven-year history. More than 900 clinicians, investors, and executives will descend upon the Planet Hollywood Hotel in Las Vegas to grab a glimpse of novel new treatments for ophthalmology disorders. Three dozen…

Read More

Looking Deep at Extended Depth-of-Focus IOLs

Looking Deep at Extended Depth-of-Focus IOLs

Multifocal IOLs, perhaps the best established solution to the problem of enabling post-cataract patients to see clearly at all distances, work by incorporating discrete refractive optical zones or diffractive echelettes into the lens. Accommodating IOLs, which aim to provide the same benefit, use ciliary muscle power to move the lens and/or change its shape to…

Read More

FDA Making the Rounds in Ophthalmology

FDA Making the Rounds in Ophthalmology

Over the past week, news about the FDA has been flooding the inboxes of ophthalmology watchers. The most notable news came Shire plc. The regulatory agency requested that Shire conduct an additional clinical trial as part of a complete response letter for the company’s NDA for lifitegrast, a potential treatment for dry eye disease in…

Read More

Premium IOLs: Two Outliers with Mainstream Potential

Premium IOLs: Two Outliers with Mainstream Potential

A problem that plagues refractive cataract surgery is the difficulty of determining the IOL power that will achieve each patient’s refractive target. In the old days, if a post-cataract patient wasn’t satisfied with their vision, they simply wore a pair of glasses. But patients paying thousands of dollars for a premium IOL are not satisfied…

Read More

Google Lens Clinical Trials to Start in 2016

Google Lens Clinical Trials to Start in 2016

Novartis, through its Alcon eye-care division, intends to start clinical trials of an accommodative Google “smart” contact lens in human eyes next year, Novartis Chief Executive Joe Jimenez told the Swiss French-language newspaper Le Temps last week. “This project is progressing well,” Jimenez told Le Temps reporter Willy Boder. “When we announced the agreement a…

Read More